trial

A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics

NCTId NCT02953639
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 214 (actual)
Sponsored by Hoffmann-La Roche
Primary completion 2019-12-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
214 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2016-11-30
Primary completion
2019-12-12
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Basmisanil

Sponsors

Hoffmann-La RocheLead Sponsor

Sites

37 total
Little Rock, United StatesRogers, United StatesCulver City, United StatesGarden Grove, United StatesGlendale, United StatesLong Beach, United StatesNational City, United StatesOakland, United StatesOrange, United StatesPico Rivera, United StatesSan Diego, United StatesTorrance, United States

Linked catalysts

1
A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Imp — primary completion2019-12-12

Facts & assertions

4 sourced
Enrollment
214
Phase
PHASE2
Primary Completion Date
2019-12-12
Status
COMPLETED
relationships
The graph out of here
drug
Basmisanil
drug
lead_sponsor
Hoffmann-La Roche
company
indication
Schizophrenia
indication
Schizophrenia
indication